Optima to host post-conference workshop at Lyophilization USA

SMi Group23 - 24 October 2019, Boston, USA.
Delegates for the 5th Annual Lyophilization USA conference, taking place in Boston, will have the opportunity to attend the half-day post-conference workshop titled "Current and Future Freeze-Drying Technologies and Methods" led by Dena Flamm and Alexander Tambovzev on October 25th 2019.

Overview of the workshop

Freeze dried products are well established in the market with an increasing trend in aseptically produced lyophilized products, including peptides and proteins. This workshop will give delegates an introduction into the Physics and Thermodynamics of Freeze-Drying; including both presentation of topics and an open discussion within the group. The session will support a better understanding of the Freeze-Drying process with the different methods available in the marketas well as discuss an alternative Freeze-Drying process for consideration.

Benefits of Attending

Delegates will have the opportunity to engage in an in-depth discussion with industry experts from Optima on the latest technological developments in the Lyophilization industry. They will also gain a better understanding of the most up to date freeze-drying technology available on the market, as well as what the future of this field looks like.

This workshop will enhance delegate's knowledge on controlled nucleation, available PAT's and the future of flexible PAT processes, and alternative freeze-drying technologies including spray drying, spin freeze-drying and microwave drying.

The brochure with the full conference program and workshop information is available to download online at http://www.lyophilisation-usa.com/PR3

Workshop Leader Overview

Dena Flamm is a Business Development Manager for OptimaMachinery Corporation. She is responsible for freeze dryer development in the North American market and has over 17 years of experience in the pharmaceutical industry. Studies include, an MBA in International Management from the University of St. Thomas with an undergraduate degree in Business and Physics.

Alexander Tambovzev is a Project Engineering and Development Group Leader at Optima Pharma, Germany. The area of his responsibility is leading the project engineering of the freeze dryers as well as the R&D effort in the freeze dryer technology. In 2008, Alexander received a Ph.D. in refrigeration technology from the Technical University of Dresden with a focus on the modelling of dynamic processes. He has worked in the research and development area of refrigeration systems for commercial and industrial applications.

An early bird saving of $200 is available for bookings placed before the 30th August. Registrations can be made online at http://www.lyophilisation-usa.com/PR3

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Bayer inks deals with eleven startups under G4A Di…

Bayer announced today that the company has signed collaboration agreements with eleven digital health startups. As part of the program, Bayer will support these startup c...

Pharmacists provide patient value in team-based ca…

With inhaler in hand, Dr. Cheng Yuet went over every detail to make sure the patient understood how the drug would control their COPD symptoms. Dr. Yuet is proving what a...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

AI and big data predict which research will influe…

An artificial intelligence/machine learning model to predict which scientific advances are likely to eventually translate to the clinic has been developed by Ian Hutchins...

Discovery of new source of cancer antigens may exp…

For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University's Biodesign Institute have pooled their energies into an often scoffed-...

Chinese activists protest the use of traditional t…

In the West, the number of people challenging scientific authority has been growing in past decades. This has, among other things, led to a decline in the support for mas...